Your browser doesn't support javascript.
loading
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
Brown, Fiona C; Still, Eric; Koche, Richard P; Yim, Christina Y; Takao, Sumiko; Cifani, Paolo; Reed, Casie; Gunasekera, Shehana; Ficarro, Scott B; Romanienko, Peter; Mark, Willie; McCarthy, Craig; de Stanchina, Elisa; Gonen, Mithat; Seshan, Venkatraman; Bhola, Patrick; O'Donnell, Conor; Spitzer, Barbara; Stutzke, Crystal; Lavallée, Vincent-Philippe; Hébert, Josée; Krivtsov, Andrei V; Melnick, Ari; Paietta, Elisabeth M; Tallman, Martin S; Letai, Anthony; Sauvageau, Guy; Pouliot, Gayle; Levine, Ross; Marto, Jarrod A; Armstrong, Scott A; Kentsis, Alex.
Afiliação
  • Brown FC; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Still E; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Koche RP; Center for Epigenetics Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yim CY; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Takao S; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Cifani P; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Reed C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gunasekera S; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ficarro SB; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Romanienko P; Mouse Genetics Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mark W; Mouse Genetics Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • McCarthy C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • de Stanchina E; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gonen M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Seshan V; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bhola P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • O'Donnell C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Spitzer B; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Stutzke C; PhosphoSolutions, Aurora, Colorado.
  • Lavallée VP; The Leucegene Project at Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec, Canada.
  • Hébert J; Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
  • Krivtsov AV; The Leucegene Project at Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec, Canada.
  • Melnick A; Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
  • Paietta EM; Quebec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
  • Tallman MS; Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Letai A; Center for Epigenetics Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sauvageau G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pouliot G; Departments of Pediatrics, Pharmacology, and Physiology and Biophysics, Weill Cornell Medical College, Cornell University, New York, New York.
  • Levine R; Montefiore Medical Center-North Division, Albert Einstein College of Medicine, Bronx, New York, New York.
  • Marto JA; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Armstrong SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kentsis A; Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 8(4): 478-497, 2018 04.
Article em En | MEDLINE | ID: mdl-29431698
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Regulação Leucêmica da Expressão Gênica / Processamento de Proteína Pós-Traducional / Resistencia a Medicamentos Antineoplásicos / Fatores de Transcrição MEF2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Regulação Leucêmica da Expressão Gênica / Processamento de Proteína Pós-Traducional / Resistencia a Medicamentos Antineoplásicos / Fatores de Transcrição MEF2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article